AML1 gene over-expression in childhood acute lymphoblastic leukemia

Leukemia

Volumn 16, Issue 4, 2002, Pages 658-668

  Mikhail, F M ^a,b   Serry, K A ^a   Hatem, N ^a   Mourad, Z I ^a   Farawela, H M ^c   El Kaffash, D M ^a   Coignet, L ^d   Nucifora, G ^b  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c CAIRO UNIVERSITY   (Egypt)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AML1; Childhood ALL; Gene over expression

Indexed keywords

DNA; TRANSCRIPTION FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL LINEAGE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BINDING; EGYPT; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE FUSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; MALE; METAPHASE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; TRISOMY 21;

EID: 85014143894     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402399     Document Type: Review

References (47)

1. Cancer incidence, survival and mortality for children younger than age 15 years
2. International Incidence of Childhood Cancer
3. The classification of acute leukaemia
4. Childhood leukemia
5. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis
6. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia
7. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multi center therapy trials
8. High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan
9. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia
10. TEL gene rearrangements in myeloid malignancy
11. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
12. The TEL gene products: Nuclear phosphoproteins with DNA binding properties
13. Oligomerization of the ABL tyrosine kinase by the ets protein TEL in human leukemia
14. TEL/AML1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
15. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
16. Identification of AML1 and the (8;21) translocation protein (AML1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for the DNA binding and protein-protein interaction
17. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor
18. Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2α
19. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
20. The t(12;21) of acute lymphoblastic leukemia results in tel-aml1 gene fusion
21. The t(12;21) translocation converts AML1-B from an activator to a repressor of transcription
22. Both TEL and AML1 contribute repression domains to the t(12;21) fusion protein
23. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promotor
24. Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21)
25. The 12;21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia
26. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphoblastic leukemia
27. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia
28. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias
29. AML1 gene amplification: A novel finding in childhood acute lymphoblastic leukemia
30. Amplification of AML1 in childhood acute lymphoblastic leukemias
31. Chromosome 21 abnormalities with AML1 amplification in acute lymphoblastic leukemia
32. Risks of leukemia and solid tumors in individuals with Down's syndrome
33. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia
34. French-American-British (FAB) Co-operative Group, proposals for the classification of the acute leukaemias
35. Age at diagnosis in childhood acute lymphoblastic leukemia
36. Current status of cytogenetic research in childhood acute lymphoblastic leukemia
37. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia
38. Genomic organization of TEL: The human ETS-variant gene 6
39. Epidemiology and immunological phenotype of childhood ALL in Greece
40. T-cell acute lymphoblastic leukemia in Israel: Clinical and laboratory features
41. Immunological subtypes of childhood acute lymphoblastic leukemia in Bulgaria
42. Cytogenetic and FISH studies of a single center consecutive series of 152 childhood acute lymphoblastic leukemia
43. Acute leukemias with structurally altered core binding factor subunits t(8;21), inv(16), and t(12;21)) - Meeting Report
44. CBFα2 (AML1) translocations with novel partner chromosomes in myeloid leukemia: Association with prior therapy
45. A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations
46. Identification of two new translocations that disrupt the AML1 gene